查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
罕見病基因檢測市場規模、份額和趨勢分析報告：按疾病類型（神經病學、CVD）、專業（分子、生化）、技術（NGS、基於PCR）、用戶、細分市場預測，2022-2030
市場調查報告書
商品編碼
1122146

罕見病基因檢測市場規模、份額和趨勢分析報告：按疾病類型（神經病學、CVD）、專業（分子、生化）、技術（NGS、基於PCR）、用戶、細分市場預測，2022-2030

Rare Disease Genetic Testing Market Size, Share & Trends Analysis Report By Disease Type (Neurological, CVDs), By Specialty (Molecular, Biochemical), By Technology (NGS, PCR-based), By End Use, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

罕見病基因檢測市場增長和趨勢

根據 Grand View Research, Inc. 的一份新報告，到 2030 年，全球罕見病基因檢測市場規模預計將達到 25.2 億美元，在預測期內的複合年增長率為 13.94%。對抗罕見疾病的有效監管計劃是該行業的主要驅動力之一。此外，提供相關疾病數據和相關信息的大量註冊機構的存在促進了過去幾年的收入增長。預計將繼續召開會議以提高對罕見和超罕見疾病的認識，以推動診斷試劑盒和服務的採用。例如，位於英國、德國、荷蘭和波蘭的 Ergomed 和 PSR Orphanexpert 正在參與旨在提高對該領域認識的各種活動。

此外，加拿大罕見病組織 (CORD) 提供了一個強大的平台，用於簡化專門用於管理該疾病患者的醫療保健政策和醫療保健系統。該機構與臨床醫生、研究人員、政府和診斷行業合作，推動該國所有罕見疾病的研發、診斷、治療和服務提供。根據美國國立衛生研究院 (NIH) 的數據，約有 3000 萬美國人被證實患有 7,000 多種已知罕見疾病中的一種。隨著意識的提高，預計未來接受疾病檢測的患者人數將會增加。在美國，設立罕見病日是為了提高認識並促進該領域的發展。

罕見病臨床研究網絡 (RDCRN) 的存在也是一個行業積極的、由 NIH 資助的研究網絡，由 23 個活躍的財團和研究小組組成，包括致力於診斷和治療疾病的患者、研究人員和臨床醫生。在 COVID-19 大流行中，患有未確診罕見病的患者面臨著重大的健康挑戰。根據一組美國研究人員於 2021 年 1 月發表的一項研究，迫切需要開發能夠緩解影響患有罕見和未確診疾病 (RUD) 的患者和家庭的嚴峻挑戰的方法。這些挑戰包括診斷和預後的不確定性以及醫療複雜性，這可能導致健康狀況惡化。

為了應對大流行帶來的挑戰，患者倡導團體和專業團體積極參與這些挑戰。例如，稀有染色體倡導組織 (Unique)、英國醫學基因組學學會和英國遺傳聯盟正在積極努力支持、倡導和告知患有該疾病的患者。一些罕見病仍未分類。慈善機構 SWAN UK 估計，英國每年約有 6,000 名兒童出生時患有遺傳疾病，但該機構表示，這些疾病非常罕見，無法命名。你不能。因此，目前不可能根據證據做出適當的診斷或預測治療的預後。目前，據說在英國接受基因檢測的兒童中約有 50% 沒有得到明確的診斷。

大約 50% 的學習障礙兒童和 60% 的先天性疾病兒童沒有得到明確的診斷以確定他們的殘疾原因。此外，患者和家屬對診斷和基因檢測缺乏認識進一步阻礙了該行業的發展。北美在 2021 年主導了該行業，原因是其罕見病高發、大量註冊、在該領域擁有相當規模的研發設施以及對診斷的大量投資。由於存在大量專注於疾病控制的組織，預計亞太地區將在預測期內實現最快的複合年增長率。

罕見病基因檢測市場報告亮點

2021年，免疫疾病領域將佔據很大份額。增加多發性硬化症病例將推動增長，因為它是該細分市場的重點關注領域之一。

從技術上看，NGS 細分市場預計將在 2022 年至 2030 年期間實現最快的複合年增長率。

這是由於基於 NGS 的基因組可用於測試癌症、神經系統疾病、心血管疾病、兒童疾病、精神疾病和其他罕見疾病的可用性和採用。

由於在研究和臨床環境中的廣泛採用，分子基因檢測專業部門在 2021 年佔最大的收入份額。增加免 CLIA 分子遺傳學檢測也提供了有利可圖的增長機會

研究機構和 CRO 最終用戶部門在 2021 年領先行業，因為研究機構和 CRO 進行了大量的基因測試

目錄

第一章研究方法論

  • 調查假設
  • 調查方法
  • 信息採購
  • 信息或數據分析
  • 市場製定和驗證
  • 市場模式
    • 市場研究，按疾病分類
    • 技術市場研究
    • 市場研究，按專業
    • 按最終用途進行的市場研究
    • 區域分析
    • 公司市場份額分析

第二章執行摘要

  • 市場概況

3. 市場變量、趨勢和範圍

  • 市場細分
  • 罕見病基因檢測市場：行業金字塔分析
    • 母公司市場展望
    • 相關/子公司市場展望
  • 2021 年技術滲透率和增長前景圖
  • 按因素（政法、經濟、技術）的 SWOT 分析
  • 波特五力分析
  • COVID-19 影響分析
    • COVID-19 期間的罕見病基因檢測解決方案

第四章行業展望

  • 市場動態
    • 市場驅動力分析
      • 擴大罕見病患者登記
      • 降低測序成本和疾病診斷的技術進步
      • 啟動罕見病診斷項目和新產品開發
    • 市場約束分析
      • 缺乏有效的診斷框架
      • 與基因檢測和數據管理相關的技術挑戰
    • 市場機會分析
      • 政府和監管部門對罕見病診斷的支持
    • 市場問題分析
      • 對罕見病的認識有限
  • 監管框架
    • 美國
    • 歐洲
    • 中國
    • 日本
  • 重大交易及戰略聯盟分析
    • 新產品發布
    • 併購
    • 合夥
  • 罕見病基因檢測市場：公司市場份額分析

第 5 章按疾病分類的業務分析

  • 罕見病基因檢測市場：疾病類型變異分析
  • 神經系統疾病
  • 免疫疾病
  • 血液病
  • 內分泌/代謝疾病
  • 癌症
  • 肌肉骨骼疾病
  • 心血管疾病 (Cvd)
  • 皮膚病
  • 其他罕見病

第六章技術業務分析

  • 罕見病基因檢測市場：技術波動分析
  • 新一代測序 (NGS)
    • 全外顯子組測序 (WES)
    • 全基因組測序（WGS）
  • 陣列技術
  • 基於 PCR 的檢測
  • 魚
  • 桑格測序
  • 核型分析

第 7 章專業業務分析

  • 分子遺傳學檢測
  • 染色體基因檢測
  • 生化基因檢測

第 8 章最終用途業務分析

  • 研究和CRO
  • 診斷實驗室
  • 醫院和診所

第九章區域業務分析

  • 罕見病基因檢測市場：區域趨勢分析
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 西班牙
    • 法國
    • 意大利
    • 荷蘭
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 新加坡
    • 澳大利亞
    • 東南亞
  • 拉丁美洲
    • 巴西
  • 中東和非洲
    • 南非

第十章公司簡介

  • 戰略框架
  • 公司參與者的分類
  • 公司簡介
    • CENTOGENE NV
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • INVITAE CORPORATION
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • 3 BILLION, INC.
      • 公司簡介
      • 產品基準
      • 戰略舉措
    • ARUP LABORATORIES
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • EUROFINS SCIENTIFIC
      • 公司簡介
      • EUROFINS Genoma Group Srl a socio unico
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • STRAND LIFE SCIENCES
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • QUEST DIAGNOSTICS INCORPORATED
      • 公司簡介
      • Blueprint Genetics Oy
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • PERKINELMER GENOMICS
      • 公司簡介
      • 財務績效
      • 產品基準
    • REALM IDX, INC.
      • 公司簡介
      • Ambry Genetics
      • 公司簡介
      • 財務績效
      • 財務業績：AMBRY GENETICS
      • 產品基準
      • 戰略舉措
    • PSOMAGEN INC. (MACROGEN, INC.)
      • 公司簡介
      • 產品基準
      • 戰略舉措
    • BAYLOR GENETICS
      • 公司簡介
      • 產品基準
      • 戰略舉措
    • COLOR GENOMICS, INC.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • HEALTH NETWORK LABORATORIES
      • 公司簡介
      • 結締組織基因檢測
      • 公司簡介
      • 產品基準
      • 戰略舉措
    • PREVENTION GENETICS
      • 公司簡介
      • 產品基準
      • 戰略舉措
    • PROGENITY, INC.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • COOPERSURGICAL, INC.
      • 公司簡介
      • Genesis Genetics
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • FULGENT GENETICS INC,
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • MYRIAD GENETICS, INC.
      • 公司簡介
      • Counsyl, Inc.
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 公司簡介
      • Sequenom
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • OPKO HEALTH, INC.
      • 公司簡介
      • Bio-Reference Laboratories
      • 公司簡介
      • GENEDX
      • 公司簡介
      • 財務績效
      • 產品基準
      • 戰略舉措
    • ARTEMIS DNA
      • 公司簡介
      • 產品基準
Product Code: GVR-4-68038-695-0

Rare Disease Genetic Testing Market Growth & Trends:

The global rare disease genetic testing market size is expected to reach USD 2.52 billion by 2030, registering a CAGR of 13.94% over the forecast period, according to a new report by Grand View Research, Inc. Effective regulatory plans to combat rare disease is one of the key drivers of the industry. Furthermore, the presence of a substantial number of registries that provide data and relevant information about related diseases has aided in revenue growth over the past years. Ongoing conferences to raise awareness about rare and ultra-rare conditions are anticipated to boost the adoption of diagnostic kits and services. For instance, Ergomed and PSR Orphan Experts, with their offices in the U.K., Germany, the Netherlands, Poland, and other countries, participate in various activities that are aimed at raising awareness in this area.

Moreover, the Canadian Organization for Rare Disorders (CORD) offers a strong platform to streamline health policy and a healthcare system that is dedicated to the management of patients with disorders. The agency works with clinicians, researchers, governments, and the diagnostic industry to advance R&D, diagnosis, treatment, and service availability for all rare conditions in the country. As per the National Institutes of Health (NIH), around 30 million Americans have been identified with one of 7,000+ known rare diseases. The number of patients undergoing disease testing is expected to increase in the coming years with growing awareness. The U.S. celebrates Rare Disease Day and promotes developments in this area by raising awareness.

In addition, the presence of the Rare Diseases Clinical Research Network (RDCRN), an NIH-funded research network of 23 active consortia or research groups that includes patients, researchers, and clinicians who are focused on the diagnosis & treatment of disorders is anticipated to positively impact the industry. Amidst the COVID-19 pandemic, patients with undiagnosed and rare diseases have been facing significant health challenges. According to a study published in January 2021 by a group of researchers from the U.S., there is an urgent need for the development of approaches that can reduce the serious challenges affecting Rare & Undiagnosed diseases (RUD) patients and families. The challenges include diagnostic and/or prognostic uncertainty coupled with medical complexity leading to poor health outcomes.

In response to the challenges created by the pandemic, patient support groups and professional societies are actively involved in addressing these challenges. For instance, the Rare Chromosome Support Group (Unique), the British Society for Genomic Medicine, and Genetic Alliance U.K. are actively involved in supporting, advocating, and providing information to patients with diseases. Several rare conditions remain unclassified. The charity SWAN U.K. estimated that around 6,000 children are born each year with genetic conditions in the U.K. As per the agency, the conditions are extremely rare and cannot be named. Thus, there is a lack of proper diagnosis and prognosis for evidence-based treatment. At present, around 50% of the children who undergo genetic testing in the U.K. would not receive a confirmed diagnosis.

Around 50% of the children with learning disabilities and approximately 60% of children with congenital conditions do not receive a definitive diagnosis to identify the cause of their disabilities. Furthermore, the lack of awareness among patients and families about diagnosis and genetic testing has further impeded the industry's growth. North America dominated the industry in 2021 due to the high incidence of rare diseases, a large number of registries, the presence of substantial numbers of R&D facilities in this area, and extensive investments in diagnosis. Asia Pacific is expected to register the fastest CAGR during the forecast years owing to the presence of a substantial number of organizations that are focusing on disease management.

Rare Disease Genetic Testing Market Report Highlights:

  • The immunological disorders segment held a significant revue share in 2021. A rise in the cases of multiple sclerosis drives the growth as is one of the key focus areas in this segment
  • Based on technology, the NGS segment is expected to register the fastest CAGR from 2022 to 2030
  • This is due to the availability & adoption of NGS-based gene panels for cancer, neurologic disease, CVD, pediatric conditions, psychiatric disorders, and another rare disease testing
  • The molecular genetic tests specialty segment held the largest revenue share in 2021 due to the high adoption in research & clinical settings. A rise in CLIA-waived molecular genetic tests also offers lucrative growth opportunities
  • The research laboratories & CROs end-user segment led the industry in 2021 owing to a large number of genetic tests conducted in research laboratories and CROs

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Research Assumptions
  • 1.2 Research Methodology
  • 1.3 Information Procurement
  • 1.4 Information or Data Analysis
  • 1.5 Market Formulation & Validation
  • 1.6 Market Model
    • 1.6.1 Market Study, By Disease
    • 1.6.2 Market Study, By Technology
    • 1.6.3 Market Study, By Specialty
    • 1.6.4 Market Study, By End Use
    • 1.6.5 Regional Analysis
    • 1.6.6 Company Market Share Analysis

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Market Variables, Trends, & Scope

  • 3.1 Market Segmentation
  • 3.2 Rare Disease Genetic Testing Market: Industry Pyramid Analysis
    • 3.2.1 Parent Market Outlook
    • 3.2.2 Related/Ancillary Market Outlook
  • 3.3 Penetration and Growth Prospect Mapping for Technology, 2021
  • 3.4 SWOT analysis, by a factor (Political & legal, economic, and technological)
  • 3.5 Porter's Five Forces Analysis
  • 3.6 COVID-19 Impact Analysis
    • 3.6.1 Rare Disease Genetic Testing Solutions During Covid-19

Chapter 4 Industry Outlook

  • 4.1 Market Dynamics
    • 4.1.1 Market Driver Analysis
      • 4.1.1.1 Expanding patient registry for rare disease
      • 4.1.1.2 Declining Sequencing Cost & Technological Advancements In Disease Diagnosis
      • 4.1.1.3 Launch Of Programs & New Product Development In Rare Disease diagnosis
    • 4.1.2 Market Restraint Analysis
      • 4.1.2.1 Absence Of Effective Diagnosis Framework
      • 4.1.2.2 Technical Challenges Associated With Genetic Tests & Data Management
    • 4.1.3 Market Opportunity Analysis
      • 4.1.3.1 Government & Regulatory Support For Rare Disease Diagnosis
    • 4.1.4 Market Challenge Analysis
      • 4.1.4.1 Limited Awareness about The Rare Disease Conditions
  • 4.2 Regulatory Framework
    • 4.2.1 U.S.
    • 4.2.2 Europe
    • 4.2.3 China
    • 4.2.4 Japan
  • 4.3 Major Deals And Strategic Alliances Analysis
    • 4.3.1 New Product Launch
    • 4.3.2 Mergers And Acquisitions
    • 4.3.3 Partnerships
  • 4.4 Rare Disease Genetic Testing Market: Company Market Share Analysis

Chapter 5 Disease Type Business Analysis

  • 5.1 Rare Disease Genetic Testing Market: Disease Type Movement Analysis
  • 5.2 Neurological Diseases
    • 5.2.1 Global Genetic Testing Market For Rare Neurological Diseases, 2018 - 2030 (USD Million)
  • 5.3 Immunological Disorders
    • 5.3.1 Global Genetic Testing Market For Rare Immunological Disorders, 2018 - 2030 (USD Million)
  • 5.4 Hematology Diseases
    • 5.4.1 Global Genetic Testing Market For Rare Hematology Diseases, 2018 - 2030 (USD Million)
  • 5.5 Endocrine & Metabolism Diseases
    • 5.5.1 Global Genetic Testing Market For Rare Endocrine & Metabolism Diseases, 2018 - 2030 (USD Million)
  • 5.6 Cancer
    • 5.6.1 Global Genetic Testing Market For Rare Cancer Forms, 2018 - 2030 (USD Million)
  • 5.7 Musculoskeletal Disorders
    • 5.7.1 Global Genetic Testing Market For Rare Musculoskeletal Disorders, 2018 - 2030 (USD Million)
  • 5.8 Cardiovascular Disorders (Cvd)
    • 5.8.1 Global Genetic Testing Market For Rare Cardiovascular Disorders, 2018 - 2030 (USD Million)
  • 5.9 Dermatology Diseases
    • 5.9.1 Global Genetic Testing Market For Rare Dermatology Diseases, 2018 - 2030 (USD Million)
  • 5.10 Other Rare Diseases
    • 5.10.1 Global Genetic Testing Market For Other Rare Diseases, 2018 - 2030 (USD Million)

Chapter 6 Technology Business Analysis

  • 6.1 Rare Disease Genetic Testing Market: Technology Movement Analysis
  • 6.2 Next Generation Sequencing (NGS)
    • 6.2.1 Global NGS-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
    • 6.2.2 Whole Exome Sequencing (WES)
      • 6.2.2.1 Global WES-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
    • 6.2.3 Whole Genome Sequencing (WGS)
      • 6.2.3.1 Global WGS-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.3 Array Technology
    • 6.3.1 Global Array Technology-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.4 Pcr-Based Testing
    • 6.4.1 Global Pcr-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.5 Fish
    • 6.5.1 Global Fish-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.6 Sanger Sequencing
    • 6.6.1 Global Sanger Sequencing-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 6.7 Karyotyping
    • 6.7.1 Global Karyotyping-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)

Chapter 7 Speciality Business Analysis

  • 7.1 Molecular Genetic Tests
    • 7.1.1 Global Molecular Genetic Tests Market For Rare Diseases, 2018 - 2030 (USD Million)
  • 7.2 Chromosomal Genetic Tests
    • 7.2.1 Global Chromosomal Genetic Tests Market For Rare Diseases, 2018 - 2030 (USD Million)
  • 7.3 Biochemical Genetic Tests
    • 7.3.1 Global Biochemical Genetic Tests Market For Rare Diseases, 2018 - 2030 (USD Million)

Chapter 8 End-Use Business Analysis

  • 8.1 Research Laboratories & CROs
    • 8.1.1 Global Research Laboratories & CROs-based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 8.2 Diagnostic Laboratories
    • 8.2.1 Global Diagnostic Laboratories-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)
  • 8.3 Hospitals & Clinics
    • 8.3.1 Global Hospitals & Clinics-Based Rare Disease Genetic Testing Market, 2018 - 2030 (USD Million)

Chapter 9 Regional Business Analysis

  • 9.1 Rare Diseases Genetic Testing Market: Regional Movement Analysis
  • 9.2 North America
    • 9.2.1 North America Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.2.2 U.S.
      • 9.2.2.1 U.S. Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.2.3 Canada
      • 9.2.3.1 Canada Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.3 Europe
    • 9.3.1 Europe Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.2 Germany
      • 9.3.2.1 Germany Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.3 U.K.
      • 9.3.3.1 U.K. Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.4 Spain
      • 9.3.4.1 Spain Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.5 France
      • 9.3.5.1 France Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.6 Italy
      • 9.3.6.1 Italy Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.3.7 The Netherlands
      • 9.3.7.1 The Netherlands Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.4 Asia Pacific
    • 9.4.1 Asia Pacific Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.2 Japan
      • 9.4.2.1 Japan Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.3 China
      • 9.4.3.1 China Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.4 India
      • 9.4.4.1 India Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.5 South Korea
      • 9.4.5.1 South Korea Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.6 Singapore
      • 9.4.6.1 Singapore Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.7 Australia
      • 9.4.7.1 Australia Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.4.8 South East Asia
      • 9.4.8.1 South East Asia Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.5 Latin America
    • 9.5.1 Latin America Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.5.2 Brazil
      • 9.5.2.1 Brazil Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 9.6 Middle East And Africa
    • 9.6.1 Middle-East And Africa Rare Disease Genetic Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 9.6.2 South Africa
      • 9.6.2.1 South Africa rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 10 Company Profiles

  • 10.1 Strategy Framework
  • 10.2 Company Participant categorization
  • 10.3 Company Profiles
    • 10.3.1 CENTOGENE N.V.
      • 10.3.1.1 Company overview
      • 10.3.1.2 Financial performance
      • 10.3.1.3 Product benchmarking
      • 10.3.1.4 Strategic initiatives
    • 10.3.2 INVITAE CORPORATION
      • 10.3.2.1 Company overview
      • 10.3.2.2 Financial Performance
      • 10.3.2.3 Product benchmarking
      • 10.3.2.4 Strategic initiatives
    • 10.3.3 3 BILLION, INC.
      • 10.3.3.1 Company overview
      • 10.3.3.2 Product benchmarking
      • 10.3.3.3 Strategic initiatives
    • 10.3.4 ARUP LABORATORIES
      • 10.3.4.1 Company overview
      • 10.3.4.2 Financial Performance
      • 10.3.4.3 Product benchmarking
      • 10.3.4.4 Strategic initiatives
    • 10.3.5 EUROFINS SCIENTIFIC
      • 10.3.5.1 Company overview
      • 10.3.5.2 EUROFINS Genoma Group Srl a socio unico
      • 10.3.5.2.1 Company Overview
      • 10.3.5.3 Financial Performance
      • 10.3.5.4 Product benchmarking
      • 10.3.5.5 Strategic initiatives
    • 10.3.6 STRAND LIFE SCIENCES
      • 10.3.6.1 Company overview
      • 10.3.6.2 Financial Performance
      • 10.3.6.3 Product benchmarking
      • 10.3.6.4 Strategic initiatives
    • 10.3.7 QUEST DIAGNOSTICS INCORPORATED
      • 10.3.7.1 Company overview
      • 10.3.7.2 Blueprint Genetics Oy
      • 10.3.7.2.1 Company Overview
      • 10.3.7.3 Financial Performance
      • 10.3.7.4 Product benchmarking
      • 10.3.7.5 Strategic initiatives
    • 10.3.8 PERKINELMER GENOMICS
      • 10.3.8.1 Company overview
      • 10.3.8.2 Financial Performance
      • 10.3.8.3 Product benchmarking
    • 10.3.9 REALM IDX, INC.
      • 10.3.9.1 Company overview
      • 10.3.9.2 Ambry Genetics
      • 10.3.9.2.1 Company Overview
      • 10.3.9.3 Financial Performance
      • 10.3.9.3.1 Financial Performance: AMBRY GENETICS
      • 10.3.9.4 Product benchmarking
      • 10.3.9.5 Strategic initiatives
    • 10.3.10 PSOMAGEN INC. (MACROGEN, INC.)
      • 10.3.10.1 Company overview
      • 10.3.10.2 Product benchmarking
      • 10.3.10.3 Strategic initiatives
    • 10.3.11 BAYLOR GENETICS
      • 10.3.11.1 Company overview
      • 10.3.11.2 Product benchmarking
      • 10.3.11.3 Strategic initiatives
    • 10.3.12 COLOR GENOMICS, INC.
      • 10.3.12.1 Company overview
      • 10.3.12.2 Financial performance
      • 10.3.12.3 Product benchmarking
      • 10.3.12.4 Strategic initiatives
    • 10.3.13 HEALTH NETWORK LABORATORIES
      • 10.3.13.1 Company overview
      • 10.3.13.2 Connective Tissue Gene Tests
      • 10.3.13.2.1 Company overview
      • 10.3.13.3 Product benchmarking
      • 10.3.13.4 Strategic initiatives
    • 10.3.14 PREVENTION GENETICS
      • 10.3.14.1 Company overview
      • 10.3.14.2 Product benchmarking
      • 10.3.14.3 Strategic initiatives
    • 10.3.15 PROGENITY, INC.
      • 10.3.15.1 Company overview
      • 10.3.15.2 Financial performance
      • 10.3.15.3 Product benchmarking
      • 10.3.15.4 Strategic initiatives
    • 10.3.16 COOPERSURGICAL, INC.
      • 10.3.16.1 Company overview
      • 10.3.16.2 Genesis Genetics
      • 10.3.16.2.1 Company overview
      • 10.3.16.3 Financial performance
      • 10.3.16.4 Product benchmarking
      • 10.3.16.5 Strategic initiatives
    • 10.3.17 FULGENT GENETICS INC,
      • 10.3.17.1 Company overview
      • 10.3.17.2 Financial Performance
      • 10.3.17.3 Product benchmarking
      • 10.3.17.4 Strategic initiatives
    • 10.3.18 MYRIAD GENETICS, INC.
      • 10.3.18.1 Company overview
      • 10.3.18.2 Counsyl, Inc.
      • 10.3.18.2.1 Company overview
      • 10.3.18.3 Financial Performance
      • 10.3.18.4 Product benchmarking
      • 10.3.18.5 Strategic initiatives
    • 10.3.19 LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 10.3.19.1 Company overview
      • 10.3.19.2 Sequenom
      • 10.3.19.2.1 Company overview
      • 10.3.19.3 Financial Performance
      • 10.3.19.4 Product benchmarking
      • 10.3.19.5 Strategic initiatives
    • 10.3.20 OPKO HEALTH, INC.
      • 10.3.20.1 Company overview
      • 10.3.20.2 Bio-Reference Laboratories
      • 10.3.20.2.1 Company overview
      • 10.3.20.2.2 GENEDX
      • 10.3.20.2.2.1 Company overview
      • 10.3.20.3 Financial Performance
      • 10.3.20.4 Product benchmarking
      • 10.3.20.5 Strategic initiatives
    • 10.3.21 ARTEMIS DNA
      • 10.3.21.1 Company overview
      • 10.3.21.2 Product benchmarking

List of Tables

  • Table 1 Inheritance pattern of rare diseases
  • Table 2 Distribution of registries by EU countries
  • Table 3 Rare disease policy and regulatory frameworks in EU
  • Table 4 North America rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 5 North America rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 6 North America NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 7 North America rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 8 North America rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 9 U.S. rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 10 U.S. rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 11 U.S. NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 12 U.S. rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 13 U.S. rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 14 Canada rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 15 Canada rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 16 Canada NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 17 Canada rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 18 Canada rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 19 Europe rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 20 Europe rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 21 Europe NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 22 Europe rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 23 Europe rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 24 Germany rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 25 Germany rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 26 Germany NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 27 Germany rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 28 Germany rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 29 U.K. rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 30 U.K. rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 31 U.K. NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 32 U.K. rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 33 U.K. rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 34 Spain rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 35 Spain rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 36 Spain NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 37 Spain rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 38 Spain rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 39 France rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 40 France rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 41 France NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 42 France rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 43 France rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 44 Italy rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 45 Italy rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 46 Italy NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 47 Italy rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 48 Italy rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 49 Netherlands rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 50 Netherlands rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 51 Netherlands NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 52 Netherlands rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 53 Netherlands rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Japan rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 60 Japan rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 61 Japan NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 62 Japan rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 63 Japan rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 64 China rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 65 China rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 66 China NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 67 China rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 68 China rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 69 India rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 70 India rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 71 India NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 72 India rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 73 India rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 74 South Korea rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 75 South Korea rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 76 South Korea NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 77 South Korea rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 78 South Korea rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 79 Singapore rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 80 Singapore rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 81 Singapore NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 82 Singapore rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 83 Singapore rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 84 Australia rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 85 Australia rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 86 Australia NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 87 Australia rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 88 Australia rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 89 South East Asia rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 90 South East Asia rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 91 South East Asia NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 92 South East Asia rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 93 South East Asia rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 94 Latin America rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 95 Latin America rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 96 Latin America NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 97 Latin America rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 98 Latin America rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 99 Brazil rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 100 Brazil rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 101 Brazil NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 102 Brazil rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 103 Brazil rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 104 MEA rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 105 MEA rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 106 MEA NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 107 MEA rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 108 MEA rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
  • Table 109 South Africa rare disease genetic testing market estimates & forecasts, by disease type, 2018 - 2030 (USD Million)
  • Table 110 South Africa rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 111 South Africa NGS - based rare disease genetic testing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 112 South Africa rare disease genetic testing market estimates & forecasts, by specialty, 2018 - 2030 (USD Million)
  • Table 113 South Africa rare disease genetic testing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million) 

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain Based Sizing and Forecasting
  • Fig. 6 QFD Modelling for Market Share Assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Rare diseases by inheritance pattern
  • Fig. 9 Definition of rare diseases by region
  • Fig. 10 Prevalence of Multiple sclerosis
  • Fig. 11 Prevalence rate of selected rare diseases in 2021
  • Fig. 12 Distribution of research projects for rare diseases
  • Fig. 13 Penetration of technologies in the rare disease diagnostics market
  • Fig. 14 QFD modeling for market share assessment for specialty scope, by type
  • Fig. 15 Penetration by end-use settings
  • Fig. 16 Regional analysis of rare disease genetic testing market
  • Fig. 17 QFD modeling for company market share assessment
  • Fig. 18 QFD modeling workflow for company market share assessment
  • Fig. 19 Rare disease genetic testing market snapshot, 2021 (USD Million)
  • Fig. 21 Ancillary market analysis
  • Fig. 22 Penetration and growth prospect mapping for specialty, 2021
  • Fig. 23 SWOT analysis, by a factor (Political & legal, economic, and technological)
  • Fig. 24 Porter's Five Forces Analysis
  • Fig. 25 Rare disease genetic testing market driver impact
  • Fig. 26 Distribution of registries by affiliation in EU
  • Fig. 27 Illumina's sequencing cost per MB
  • Fig. 28 Rare disease genetic testing market restraint impact
  • Fig. 29 Challenges in rare disease diagnosis
  • Fig. 30 Company market share analysis
  • Fig. 31 Rare disease genetic testing market: Disease type outlook and key takeaways
  • Fig. 32 Rare disease genetic testing market: Disease type movement analysis
  • Fig. 33 Global genetic testing market for rare neurology diseases, 2018 - 2030 (USD Million)
  • Fig. 34 Global genetic testing market for rare immunologic disorders, 2018 - 2030 (USD Million)
  • Fig. 35 Global genetic testing market for rare hematology diseases, 2018 - 2030 (USD Million)
  • Fig. 36 Global genetic testing market for rare endocrine & metabolism diseases, 2018 - 2030 (USD Million)
  • Fig. 37 Global genetic testing market for rare cancer forms, 2018 - 2030 (USD Million)
  • Fig. 38 Global genetic testing market for rare musculoskeletal disorders, 2018 - 2030 (USD Million)
  • Fig. 39 Global genetic testing market for rare cardiovascular disorders, 2018 - 2030 (USD Million)
  • Fig. 40 Global genetic testing market for rare dermatology diseases, 2018 - 2030 (USD Million)
  • Fig. 41 Global genetic testing market for other rare diseases, 2018 - 2030 (USD Million)
  • Fig. 42 Rare disease genetic testing market: Technology outlook and key takeaways
  • Fig. 43 Rare disease genetic testing market: Technology movement analysis
  • Fig. 44 DNA sequencing cost per genome
  • Fig. 45 DNA sequencing cost per genome
  • Fig. 46 Global NGS-based Rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 47 Comparison of growth in genetic testing units for exome & targeted exome, custom genes, large (>500 gene) panels
  • Fig. 48 Global WES-based rare disease genetic testing market 2018 - 2030 (USD Million)
  • Fig. 49 Global WGS-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 50 Global array specialty-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 51 Global PCR-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 52 Global FISH-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 53 Global sanger sequencing-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 54 Global karyotyping-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 55 Rare disease genetic testing market: Specialty outlook and key takeaways
  • Fig. 56 Rare disease genetic testing market: Specialty movement analysis
  • Fig. 57 DNA sequencing cost per Mb
  • Fig. 58 Global molecular genetic tests market for rare diseases, 2018 - 2030 (USD Million)
  • Fig. 59 Global chromosomal genetic tests market for rare diseases, 2018 - 2030 (USD Million)
  • Fig. 60 Global biochemical genetic tests market for rare diseases, 2018 - 2030 (USD Million)
  • Fig. 61 Rare disease genetic testing market: End-use outlook and key takeaways
  • Fig. 62 Rare disease genetic testing market: End-use movement analysis
  • Fig. 63 Global research laboratories & CROs-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 64 Global diagnostic laboratories-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 65 Global hospitals & clinics-based rare disease genetic testing market, 2018 - 2030 (USD Million)
  • Fig. 66 Rare disease genetic testing market: Regional outlook and key takeaways
  • Fig. 67 Rare disease genetic testing market: Regional movement analysis
  • Fig. 68 North America
  • Fig. 69 North America rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 U.S.
  • Fig. 71 U.S. rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Canada
  • Fig. 73 Canada rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Europe
  • Fig. 75 Europe rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Germany
  • Fig. 77 Germany rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 U.K.
  • Fig. 79 U.K. rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Spain
  • Fig. 81 Spain rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 France
  • Fig. 83 France rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Italy
  • Fig. 85 Italy rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 The Netherlands
  • Fig. 87 The Netherlands rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Asia-Pacific
  • Fig. 89 Asia-Pacific rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 Japan
  • Fig. 91 Japan rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 China
  • Fig. 93 China rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 94 India
  • Fig. 95 India rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 96 South Korea
  • Fig. 97 South Korea rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 98 Singapore
  • Fig. 99 Singapore rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 100 Australia
  • Fig. 101 Australia rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 102 South East Asia
  • Fig. 103 South East Asia rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 104 Latin America
  • Fig. 105 Latin America rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 106 Brazil
  • Fig. 107 Brazil rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 108 Middle East & Africa
  • Fig. 109 MEA rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 110 South Africa
  • Fig. 111 South Africa rare disease genetic testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 112 Strategy framework
  • Fig. 113 Company participant categorization